Literature DB >> 6266683

The use of four-drug combination chemotherapy (D.A.V.E.) in the treatment of advanced Wilms' tumour.

D B Dunger, J S Malpas, J R Graham-Pole, M R Sandland, A G Stansfeld, J E Freeman.   

Abstract

A study was begun in 1971 at St. Bartholomew's Hospital with a combination of 4 drugs, dactinomycin (actinomycin D), adriamycin, vincristine and Endoxan (cyclophosphamide) (D.A.V.E.), together with surgery and radiation, in the treatment of stage III and stage IV Wilms' tumour. Seventy-one percent of the children treated achieved complete response. The median survival from diagnosis was 19 months, and in those children achieving complete response the median disease-free survival has not yet been reached. Toxicity was not a serious problem. The study group is compared with a group of children treated at this hospital before 1971. There is an improved survival in the children treated with D.A.V.E. Children who have relapsed with stage I or stage II disease may also respond. This four-drug combination was well tolerated and effective, and confirms recent experience suggesting that intensive multiple-drug regimens may be curative even in advanced disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6266683     DOI: 10.1007/bf00434386

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Clinical studies on actinomycin D with special reference to Wilms' tumor in children.

Authors:  S FARBER; G D'ANGIO; A EVANS; A MITUS
Journal:  Ann N Y Acad Sci       Date:  1960-10-05       Impact factor: 5.691

2.  Potentiation of x-ray effects by actinomycin D.

Authors:  G J D'ANGIO; S FARBER; C L MADDOCK
Journal:  Radiology       Date:  1959-08       Impact factor: 11.105

3.  Adriamycin in Wilms's tumor previously treated with chemotherapy.

Authors:  F F Bellani; M Gasparini; G Bonadonna
Journal:  Eur J Cancer       Date:  1975-08       Impact factor: 9.162

4.  Treatment of mixed tumors of the kidney in childhood.

Authors:  R E GROSS; E B D NEUHAUSER
Journal:  Pediatrics       Date:  1950-12       Impact factor: 7.124

5.  Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study.

Authors:  J B Beckwith; N F Palmer
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

Review 6.  Wilm's tumor: an update.

Authors:  G J D'Angio; J B Beckwith; N E Breslow; H C Bishop; A E Evans; V Farewell; D Fernbach; W E Goodwin; B Jones; L L Leape; N F Palmer; M Tefft; J A Wolff
Journal:  Cancer       Date:  1980-04-15       Impact factor: 6.860

7.  Wilms' tumor--an interdisciplinary treatment program with and without dactinomycin.

Authors:  L W Margolis; W B Smith; W M Wara; J H Kushner; A A DeLorimier
Journal:  Cancer       Date:  1973-09       Impact factor: 6.860

8.  Vincristine sulfate and radiation therapy in metastatic Wilms' tumor.

Authors:  T J Vietti; M P Sullivan; M E Haggard; T M Holcomb; D H Berry
Journal:  Cancer       Date:  1970-01       Impact factor: 6.860

9.  Vincristine, dactinomycin, and cyclophosphamide (VAC) chemotherapy for recurrent metastatic Wilms tumor in previously treated children.

Authors:  J A Ortega; G R Higgins; K O Williams; B R Wald; H Isaacs; S E Siegel
Journal:  J Pediatr       Date:  1980-03       Impact factor: 4.406

10.  VINCRISTINE (LEUROCRISTINE) SULFATE IN THE TREATMENT OF CHILDREN WITH METASTATIC WILMS' TUMOR. PEDIATRIC DIVISION, SOUTHWEST CANCER CHEMOTHERAPY GROUP.

Authors:  H E MACMAHON; M BEDIZEL; C A ELLIS
Journal:  Pediatrics       Date:  1963-11       Impact factor: 7.124

View more
  1 in total

1.  Stimulation of resistance of immunocompromised mice by a muramyl dipeptide analog.

Authors:  Y Osada; M Mitsuyama; K Matsumoto; T Une; T Otani; H Ogawa; K Nomoto
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.